CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2024

Feb 14, 2024

15 February 2024

ASX ANNOUNCEMENT

==> picture [262 x 53] intentionally omitted <==

Late lodgement of Appendix 3Y

Please find attached Appendix 3Y – Change of Director’s Interest Notice for Eric Sullivan.

During a routine internal review of the options granted to Mr. Sullivan and approved at the 2023 Annual General Meeting, a discrepancy was discovered in the Directors’ interests and disclosures.

To minimize the likelihood of such discrepancies occurring in the future, the Company has implemented additional compliance monitoring measures with the share registry.

The Company and the Directors are aware of their obligations under the Corporations Act and ASX Listing Rules 3.19A and 3.19B to provide the necessary information to meet its disclosure requirements.

Phillip Hains Company Secretary

Chimeric Therapeutics Limited ABN 68 638 835 828 www.chimerictherapeutics.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Eric Sullivan
Date of Last Notice:	31 August 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		14 December 2023
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Class		Unlisted options
Number acquired				Options 2,750,000 - 2,750,000
			Shares	Options
		Direct	-	2,750,000
		Indirect	-	-
		**Total **	-	2,750,000
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		Non-cash, see ‘nature of change’ below.	Non-cash, see ‘nature of change’ below.	Non-cash, see ‘nature of change’ below.
No. of securities held after change				Options 2,750,000 - 2,750,000
			Shares	Options
		Direct	-	2,750,000
		Indirect	-	-
		Total	-	2,750,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issue of options as approved by Chimeric Therapeutics shareholders at the Annual General Meeting held on 14 November 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011